COMPASS Pathways: COMP360 psilocybin therapy shows potential

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II

Related Keywords

London , City Of , United Kingdom , United States , Phoenix , Arizona , California , La Jolla , Friston , East Sussex , America , David Feifel , Sheppard Pratt Baltimore , Stephen Schultz , Amy Lawrence , Sheppard Pratt , Scott Aaronson , Institute For Advanced Diagnostics , Linkedin , Young , Kadima Neuropsychiatry Institute , Nasdaq , Exchange Commission , National Institute Of Mental Health , Meeting Of The American College Neuropsychopharmacology , Annual Meeting , American College , Depression Rating Scale , Chief Science Officer , Advanced Diagnostics , Principal Investigator , New England Journal , Guy Goodwin , Chief Medical Officer , Emotional Breakthrough Inventory , Five Dimensional Altered States , North America , Securities Act , Private Securities Litigation Reform Act , Open Label Study , Compass , Pathways , Omp360 , Silocybin , Therapy , Shows , Potential , Pen , Label , Study , Type , Bipolar , Disorder , Resented , Cnp ,